



3rd EU HCV Virtual Policy Summit DRAFT Programme
"Securing Wider EU Commitment to the elimination of HCV"
Wednesday, 24 March 2021
14:00 – 18:30 CET

Timing	Programme Item	Speakers
14:00 – 14:25	<p><u>Welcome and Introductory comments</u></p> <ul style="list-style-type: none"> • <i>Welcome and scene setting</i> <i>"5 years on: Revisiting the Elimination Manifesto"</i> • <i>Introductory comments on the continued need/opportunity to eliminate HCV in Europe</i> <ul style="list-style-type: none"> - <i>European Association for the Study of the Liver</i> - <i>ACHIEVE Coalition</i> - <i>WHO Europe</i> - <i>European Parliament</i> 	<p>Heiner Wedemeyer, Co-Chair HepBCPPA and Hannover Medical School, Germany</p> <p>George Papatheodoridis, Co-chair HepBCPPA and University of Athens Medical School, Greece</p> <p>Maria Buti, EU Policy Councillor, EASL</p> <p>George Kalamitsis, Co-Chair ACHIEVE Coalition</p> <p>Antons Mozalevskis, WHO Europe</p> <p>Petros Kokkalis, MEP, Greece</p>
14:25 – 14:55	<p><u>Keynote addresses</u></p> <ul style="list-style-type: none"> • <i>How the EU can help deliver on the WHO elimination goal for viral Hepatitis B and C</i> • <i>The EMCDDA's contribution to advance the elimination of HCV in Europe</i> 	<p><u>Chair:</u> Rafael Esteban, University Hospital Vall d'Hebron, Barcelona Spain, Co-Chair of HepBCPPA</p> <p>John Ryan, Director of Public Health, Country knowledge, Crisis management, DG SANTE, European Commission</p> <p>Alexis Goosdeel, Director, EMCDDA (TBC)</p>
14:55 – 15:40	<p><u>Session 1. Progress in HCV elimination in Europe</u></p> <ul style="list-style-type: none"> • <i>Facts and figures of HCV elimination in Europe</i> • <i>Care continuum and barriers</i> • <i>Synergies of harm reduction and HCV elimination</i> 	<p><u>Chairs:</u> Massimo Colombo, San Raffaele Hospital, Milan, Italy</p> <p>Markus Peck-Radosavljevic, Klinikum Klagenfurt, Austria</p> <p>Homie Razavi, Centre of Disease Analysis, USA</p> <p>Jeffrey Lazarus, ISGlobal, Spain</p> <p>Sharon Hutchinson, Glasgow Caledonian University, UK</p>

	<ul style="list-style-type: none"> • <i>Panel discussion and Q&A moderated by session chairs</i> 	
15:40 – 16:25	<p><u>Session 2. HCV diagnosis in the era of HCV elimination</u></p> <ul style="list-style-type: none"> • <i>Screening of the general population</i> • <i>Diagnosing the risk groups – the hidden and mobile population</i> • <i>From evidence to impact: reaching the elimination targets in the EU/EEA</i> • <i>Panel discussion and Q&A moderated by session chairs</i> 	<p><u>Chairs:</u> Angelos Hatzakis, Co-chair HepBCPPA and University of Athens Medical School, Greece Nurdan Tözün, Acıbadem University School of Medicine, Turkey Stanislas Pol, Hôpital Cochin, Paris, France Ruth Zimmermann, Robert Koch Institute Berlin, Germany Lina Nerlander, ECDC</p>
16:25 – 16:45	<p><u>Session 3. COVID-19 and HCV</u></p> <ul style="list-style-type: none"> • <i>Impact of COVID-19 in HCV elimination</i> • <i>Q&A</i> 	<p><u>Chair:</u> Harry Janssen, Toronto General Hospital, Canada Alessio Aghemo, Humanitas University Hospital Milan, Italy</p>
16:45 – 16:50	<p><u>Session 4a. Introduction to breakout sessions on Best Practices at the National level (PLENARY SESSION BEFORE BREAKOUT)</u></p> <ul style="list-style-type: none"> • <i>Introduction “Best Practices at the National level” breakout sessions</i> 	<p><u>Chair:</u> Mojca Maticic, University Medical Centre Ljubljana, Slovenia</p>
16:50 – 17:30	<p><u>Session 4b. Elements of an effective elimination strategy - Best Practices at the National level (3-5 [TBC] BREAKOUT SESSIONS – see details below)</u></p> <p><i>Breakout Session 1. Fast-track cities</i> <i>Breakout Session 2. ACHIEVE coalition</i> <i>Breakout Session 3. National Elimination Plans</i> <i>Breakout Session 4. Best practice case studies</i> <i>Breakout Session 5. Best practice case studies</i></p>	<p>Breakout sessions</p>


17:30 – 18:20	<p><u>Session 5. What political response/leadership?</u></p> <ul style="list-style-type: none"> • <i>EU4Health-funded network of Excellence</i> • <i>The role of European cities to eliminate HCV</i> • <i>EU for Health 2021: HCV elimination will reduce cancer</i> • <i>Presentation of Call to Action</i> • <i>Panel discussion and Q&A moderated by session chairs</i> 	<p><u>Chairs:</u> Ricardo Baptista-Leite, UNITE, MP, Portugal (TBC) Manuel Carballo, ICMHD, Switzerland</p> <p>Cristian-Silviu Busoi, MEP, Romania</p> <p>Kostas Bakoyannis, Mayor of Athens</p> <p>Aldo Patriciello, MEP, Italy (video presentation) & Tomislav Sokol, MEP Croatia</p> <p>Jeffrey Lazarus, ISGlobal, Spain</p>
18:20 – 18:30	<p><u>Concluding remarks</u></p>	<p>Heiner Wedemeyer, Co-Chair HepBCPPA and Hannover Medical School, Germany</p> <p>George Papatheodoridis, Co-chair HepBCPPA and University of Athens Medical School, Greece</p>

Details of breakout sessions – 16:50-17:30

Timing	Programme Item	Invited Speakers
16:50 – 17:30	<p><u>Session 4b. Elements of an effective elimination strategy - Best Practices at the National level (5 BREAKOUT SESSIONS)</u></p> <p>Breakout Session 1. Fast-track cities Breakout Session 2. ACHIEVE coalition Breakout Session 3. National Elimination Plans Breakout Session 4. Best practice case studies Breakout Session 5. Best practice case studies</p> <p>Moderators: 4 minutes Speakers: 8 minutes each (3 for a total of 24 minutes) Discussion: 12 minutes each</p>	
	<p><u>Breakout session 1. Fast-Track Cities</u> <i>“The Urban fight against the Hep C Epidemic – Contributions from Fast-Track Cities”</i></p> <ul style="list-style-type: none"> • <i>PWIDs: harm-reduction and supervised consumption rooms</i> • <i>Integrating Viral Hepatitis onto the Fast-Track Cities</i> • <i>Screening and Linkage to Care (SLTC) - sharing best practices in policy</i> 	<p><u>Moderator:</u> Bertrand Audoin, VP Strategic Partnerships IAPAC -International Association of Providers of AIDS Care</p> <p><u>Chair:</u> HepBCPPA Chair (TBC)</p> <p>Ivan Vukovic, Mayor of Podgorica (TBC) Johanna Rolland, Mayor of Nantes (TBC) Milena Johnova, Deputy-Mayor for Health and Equity of Prague (TBC)</p>

	<ul style="list-style-type: none"> • <i>Discussion and Q&A</i> 	
	<p><u>Breakout session 2. ACHIEVE Coalition</u> <u>Title TBC</u></p> <ul style="list-style-type: none"> • <i>Presentations TBC</i> • <i>Discussion and Q&A</i> 	<p><u>Moderator:</u> (TBC)</p> <p><u>Chair:</u> Prof. Su Wang, World Hepatitis Alliance (TBC)</p> <p>Speakers (TBC)</p>
	<p><u>Breakout session 3. National Elimination Plans</u> <u>Title TBC</u></p> <ul style="list-style-type: none"> • <i>Update on progress in the UK</i> • <i>Update on progress in Italy</i> • <i>Update on progress in Israel</i> • <i>Update on progress in Spain [TBC]</i> • <i>Discussion and Q&A</i> 	<p><u>Moderator:</u> (TBC)</p> <p><u>Chair:</u> Dr. Zobair Younossi, Inova Health System</p> <p>Mr Mark Gillyon-Powell, NHS England Dr Loreta Kondili, Istituto Superiore di Sanità, Rome, Italy Dr Yuval Dadon, National Program of Hepatitis C Elimination at Israeli Ministry of Health Dr Pilar Aparicio Azcárraga, Ministry of Health, Consumption and Social Well-being, Spain (TBC)</p>
	<p><u>Breakout session 4. Best practice case studies (1/2)</u> <u>Title TBC</u></p> <ul style="list-style-type: none"> • <i>HepCare Project, Dublin</i> • <i>Aristotle HCV, Athens and Alexandros in Thessaloniki Greece</i> • <i>HCV elimination in PWIDS in Prague</i> • <i>Discussion and Q&A</i> 	<p><u>Moderator:</u> (TBC)</p> <p><u>Chair:</u> Prof Antonio Craxi, University of Palermo</p> <p>Prof Jack Lambert, Ireland (TBC)</p> <p>Prof Vana Syspa, Greece (TBC)</p> <p>Dr David Pešek, Czech Republic (TBC)</p>
	<p><u>Breakout session 5. Best practice case studies (2/2)</u> <u>Title TBC</u></p> <ul style="list-style-type: none"> • <i>Microhepcero Catalonia: SLTC in migrant-vulnerable population</i> • <i>Dual testing of HCV and Covid-19</i> • <i>Best practice from to be determined</i> • <i>Discussion and Q&A</i> 	<p><u>Moderator:</u> (TBC)</p> <p><u>Chair:</u> Prof Laurent Castera, Department of Hepatology Hôpital Beaujon, University of Paris-VII</p> <p>Dr Joan Colom Farran, Spain</p> <p>Mr Ivan Gardini, ACE Italy (TBC)</p>

Official Partners



This event has been supported by grants from AbbVie and Gilead Sciences Europe

